Cantor Fitzgerald’s Post

Optimising operations will help biotechs facilitate movement through critical milestones, avoid delays and help navigate this most difficult program phase. Learn how biotech sponsors can mitigate costly, time-consuming changes by simplifying protocol design in part two of our biotech funding whitepaper series. https://ow.ly/ZyUc50RrXHn

Check out the latest Outcome Capital's index tracker, transaction highlights, and strategic analysis by Outcome's #lifesciences deal team. - #radiopharmaceuticals continue to garner attention with third deal in six months - Rise in mid-cap acquisitions highlights active deployment of cash in an effort to refresh #biopharma pipelines - #medtech companies merge as a strategy to gain access to public markets

Join me at the BIO CEO & Investor Conference - one of the largest investor conferences in our industry where institutional investors, industry analysts, and senior executives are shaping the future investment landscape of biotechnology. #bioceo24 #PCLX #zelenirstat #oncology #Pacylex

🔬 📈 Biotech investors and corporate development professionals We've just launched Gosset, the platform that provides insights about biotech assets. Try our demo here: https://lnkd.in/gK2mUiTm and comment on this post to get early access to the full version (or just to help us spread the word:)

Calluna Pharma is attending Bio€quity Europe conference, taking place 12-14 May, organized by BioCentury Inc. and EBD Group. Our CEO John Montana is going to be in San Sebastian next week for one of Europe’s top experiences for CEOS and investors to network, partner and discuss key issues facing the biotech industry. This is an opportunity to learn more about how to reach discussion stage with investors, discover 100+ emerging biotechs, and dive into European biotech trends. Find out more, and join us here: https://lnkd.in/dzunkQc #Biotech #Pharma #VentureCapital #BioEquityEurope #BioEquity

TPG has closed a $580 million life sciences fund for drug development startups, medical device makers and tech-enabled healthcare services companies. The fund has already backed multiple biotechs, including antibody-drug conjugates maker MBrace Therapeutics, immunology startup Santa Ana Bio, TYK2 drug developer Sudo Biosciences and oncology-focused Bicara Therapeutics, among others. Leading the fund’s investment team are partners Carolyn Ng, Shinichiro Fuse and Lucian Iancovici MD. TPG's Life Sciences Innovation unveiling on Tuesday follows a $650 million fund at Goldman Sachs, a $500 million-plus fund at JP Morgan and about two dozen funds from biotech and life sciences specialists so far this year. More in Endpoints News: #tpg #lifesciences #biotechinvesting #biotech

How will investment capital be invested in small molecule biotech in Q4 2024 and 2025?

Bonum Therapeutics' John Mulligan, Ph.D. drops a gold nugget of wisdom in today's #BusinessOfBiotech for anyone who has to make executive decisions. In other words, that's just about everybody. When prioritizing tasks, you generally have three types. Low complexity/high value — these are rare. High complexity/low value — these are abundant. High complexity/high value — these are the Goldilocks tasks. I don't know about you, but I can get confused by those abundant high-complexity/low-value tasks. They're easy to spot but sneaky about hiding their payout value. I bet discerning the difference saves a ton of time and boosts productivity.

This is ging to be a first for us: #SwissBiotechDay! Allegedly Europe’s top biotech conference, so it cannot be missed. Join me and my dear colleague Francesca Belli Novak for Swiss Biotech Day(s) on 22 and 23 April in #Basel. We will be more than happy to speak with you about either: - expanding your business to Europe, or - preparing a transaction in the Biotech/ Life Sciences space, both in the context of our network: #TheGenotypeNetwork: the first and only network of corporate and regulatory lawyers in Life Sciences. TGN aims to build a trust-based community with a view to thoroughly optimize the success of transactions, investments, and IPO’s in the life sciences space. Happy to plan a meeting via the HelloPartnering system. Speak soon. www.thegenotypenetwork.com #Biotech #Regulatory #Corporate #Network #Basel

In this upcoming webinar, Cook MyoSite's Adam Hostetler will divulge industry secrets for fostering successful biotech partnerships, detailing the importance of defining mutual goals, data sharing guidelines and more. Register now >>> https://hubs.ly/Q02xfyS80